-
2024-514889-40-00
6
2019-12-20
Hyperkalemia
-
2022-502361-15-00
5
2019-12-12
Moderate-to-Severe Plaque Psoriasis
-
2024-512732-30-00
4
2019-12-06
Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)
-
2024-514402-31-00
4
2019-09-09
Late Metachromatic Leukodystrophy (MLD)
-
2024-511972-33-00
5
2019-08-05
Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-
-
2023-508022-10-00
6
2019-07-25
Rheumatoid Arthritis
-
2023-509053-32-00
5
2019-07-17
Locoregional Hepatocellular Carcinoma (HCC)
-
2024-511885-35-00
5
2019-07-03
macular telangiectasia type 1
-
2023-509296-16-00
4
2019-06-17
Moderate to severe hidradenitis suppurativa
-
2023-503673-38-00
5
2019-05-24
Adults at high risk of cardiovascular events without prior MI or strok
-
2023-503898-38-00
5
2019-05-24
Atopic Dermatitis
-
2022-500395-57-00
5
2019-03-04
Resectable high-risk Locally Advanced Cutaneous Squamous Cell Carcinom
-
2023-505494-32-00
5
2018-10-15
Focal segmental glomerulosclerosis (FSGS)
-
2023-506543-41-00
5
2018-07-25
Multiple sclerosis (MS)
-
2024-515356-21-00
5
2018-04-17
Adult subject (18 years of age older) with low or intermediate-1 IPSS
-
2024-515600-39-00
6
2018-01-23
Adults patients suffering from rheumatoid arthritis and in adequate re
-
2024-513746-11-00
5
2017-06-08
Patient with large choroid melanoma 7 mm thick and/or more than 15 mm
-
2023-503807-27-00
4
Biliary tract carcinoma
-
2023-508992-35-00
4
Plaque Psoriasis
-
2023-510361-97-00
5
Newly Diagnosed RARA-positive Adult Patients with Higher-risk
Myelodys
-
2024-516028-33-01
5
HIV infection
-
2024-517925-25-00
4
prader-willi syndrome
-
2025-520468-16-00
4
Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable
-
2025-522054-40-00
4
Previously treated advanced melanoma